NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients

Journal of Orthopaedic Research

Volumn 27, Issue 1, 2009, Pages 135-140

  Benassi, Maria Serena ^a   Pazzaglia, Laura ^a   Chiechi, Antonella ^a   Alberghini, Marco ^a   Conti, Amalia ^a   Cattaruzza, Sabrina ^b   Wassermann, Bruna ^b   Picci, Piero ^a   Perris, Roberto ^b,c  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Clinical course; Metastasis prediction; NG2 proteoglycan; Prognosis; Soft tissue sarcomas

Indexed keywords

NG2 PROTEIN; PROTEOGLYCAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NG2 GENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; PROTEOGLYCANS; SARCOMA; SOFT TISSUE NEOPLASMS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 58149267682     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20694     Document Type: Article

References (25)

1. Campanacci M. 1999. Soft tissue tumors. In: Gaggi A, editor. Bone and soft tissue tumors. 2nd ed. Bologna: Springer-Verlag. p 841-1060.
2. Dirix LY, Van Oosterom AT. 2002. Gene-expression profiling to classify soft tissue sarcomas. Lancet 359:1263-1264.
3. Helman LJ, Meltzer P. 2003. Mechanisms of sarcoma development. Nat Rev 3:685-694.
4. Nielsen TO, West RB, Linn SC, et al. 2002. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359:1301-1307.
5. Lee YF. 2003. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytoma. Br J Cancer 88:510-515.
6. Tschoep K, Kohlmann A, Schlemmer M, et al. 2007. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 63:111-124.
7. O'Sullivan B, Bell R, Bramwell V. 2002. Sarcoma of the soft tissues. In; Souhami RL, Tannock J, Hohenberger P, Horiot JC, editors. Oxford textbook of oncology. 2nd ed. Oxford: Oxford University Press Oxford, p 2495-2523.
8. Stallcup WB. 2002. NG2 proteoglycan: past insights and future prospects. J Neurocytol 31:423-435.
9. Schwartz S, Rieder H, Schlager B, et al. 2003. Expression of the human homologue of rat NG2 in acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s(+)/CD15(+) B-cell phenotype. Leukemia 17:1589-1595.
10. Neudenberger J, Hotfilder M, Rosemann A, et al. 2006. Lack of expression of the ehondroitin sulphate proteogycan neuron-glial antigen 2 on candidate stem cell populations in pedriatic acute myeloid leukaemia/abn (11q23) and acute lymphoblastic leukaemia/t (4;11). Br J Haematol 133:337-344.
11. Cattaruzza S, Ferris R. 2006. Approaching the proteoglycome: molecular interactions of proteoglycans and their functional output. Macromol Biosci 6:667-680.
12. Chang C-C, Campoll M, Luo W, et al. 2004. Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen. Ann N Y Acad Sci 1028;340-350.
13. Virgintino D, Girolamo F, Erede M, et al. 2006. An intimate interplay between migrating pericytes and endothelial cells governs human foetal brain angiogenesis. Angiogenesis 10: 35-45.
14. Virgintino D, Ozerdem U, Girolamo F, et al. 2007. Reversal of the cellular roles in angiogenesis: implications for anti-angiogenic therapy. J Vase Res 45:129-131.
15. Coindre JM, Terrier P, Guillou L, et al. 2001. Predictive value of grade metastases development in main histological types of adult soft tissue sarcomas. A. study of 1240 patients from French Federation of Cancer Centers Sarcoma Group. Cancer 91:1914-1926.
16. l6 expression correlates with promoter methylation and poor prognosis. J Pathol 201:487-495.
17. Ottaiano A, De Chiara A, Perrone F, et al. 2004. Prognostic value of CD40 in adult soft tissue sarcomas. Clin Cancer Res 10:2824-2831.
18. de Silva MV, McMahon AD, Reid R. 2004. Prognostic factors associated with local recurrence, metastases, and tumor-related death in patients with synovial sarcoma. Am J Clin Oncol 27:113-121.
19. Ahlen J, Wejde J, Brosjo O, et al. 2005. Insulin-like growth factor type I receptor expression coprrelates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 11: 206-216.
20. Engellau J, Bendahl PO, Persson A, et al. 2005. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis growth pattern and immunostaining using whole-tumor sections and tissue microarray. Hum Pathol 36:994-1002.
21. Ferguson PC, Griffin AM, O'Sullivan B, et al. 2006. Bone invasion in extremity soft-tissue sarcoma: impact of disease outcome. Cancer 106:2692-2700.
22. Scambia G, Lovergine S, Masciullo V. 2006. RB family members as predictive and prognostic factors in human cancer. Oncogene 25:5302-5308.
23. Kim MS, Cho WH, Lee SY, et al. 2007. Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma. Anticancer Res 27:1171-1178.
24. Benassi MS, Ponticelli F, Azzoni E, et al. 2007. Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas. Histol Histopathol 22:1017-1024.
25. Chekenya M, Immervoll H. 2007. NG2/HMP proteoglycan as cancer therapeutic target. Methods Mol Biol 361:93-117.